Three years after giving a synopsis of its microbiome play with some seed funding from Malin and Hatteras Venture Partners, Artizan is raising the curtain on their first act in inflammatory bowel disease.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,